The clinical evaluation of agents for the prophylaxis and treatment of viral infections of the respiratory tract

International Journal of Pharmaceutical Medicine

Volumn 11, Issue 6, 1997, Pages 342-349

  Snell, N J C ^a   Nicholson, K G ^b   Penn, C ^c  

^a Bayer European Medical Affairs   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; PLACEBO; RIBAVIRIN; RIMANTADINE; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ARTICLE; BRONCHIOLITIS; CLINICAL TRIAL; COMMON COLD; CROUP; HANTAVIRUS PULMONARY SYNDROME; HUMAN; INFECTION PREVENTION; INFLUENZA; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LARYNGOTRACHEOBRONCHITIS; NEBULIZATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RHINITIS; RISK BENEFIT ANALYSIS; TONSILLITIS; TOPICAL DRUG ADMINISTRATION; VIRUS INFECTION; VIRUS PNEUMONIA;

EID: 0031422362     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. McIntosh K, Halonen P, Ruuskanen O. Report of a workshop on respiratory viral infections: epidemiology, diagnosis, treatment and prevention. Clinical Infectious Disease 1993; 16: 151-164.
2. Monto A. Studies of the community and family: Acute respiratory illness and infection. Epidemiologic Reviews 1994; 16: 351-373.
3. Busse W. Role and contribution of viral respiratory infections to asthma. Allergy 1993; 48: 57-61.
4. Shale D. Viral infections: a role in the lung disease of cystic fibrosis? Thorax 1992; 47: 69.
5. Betts R. Resistance to rimantadine and amantidine. Current Opinion in Infectious Disease 1991; 4: 804-808.
6. Han L, Wilson R, Slater S, Rutman A, Reed R, Snell N, Cole P. In vitro and in vivo effects of ribavirin on human respiratory epithelium. Thorax 1990; 45: 100-104.
7. Bucknall R. Why aren't antivirals effective when administered intranasally? Journal of Antimicrobial Chemotherapy 1975; 1: (Suppl. 4); 77-80.
8. Atkins P. Aerodynamic particle size testing: Impinger methods. Pharmaceutical Technology 1993; 16: 26-32.
9. Newman S. Scintigraphic assessment of therapeutic aerosols. Critical Reviews in Therapeutic Drug Carrier Systems 1993; 10: 65-109.
10. Hayden F. Combinations of antiviral agents for treatment of influenza virus infections. Journal of Antimicrobial Chemotherapy 1986; 18: (Suppl B); 177-183.
11. Tyrrell D, Cohen S, Schlorb J. Signs and symptoms in common colds. Epidemiology and Infection 1993; 111: 143-156.
12. Andrewes C. Adventures among viruses III. The puzzle of the common cold. Reviews of Infectious Disease 1989; 11: 1022-1028.
13. Tyrrell D. The efficacy and tolerance of intranasal interferons: Studies at the Common Cold Unit. Journal of Antimicrobial Chemotherapy 1986; 18: (Suppl B); 153-156.
14. Hayden F, Tranor J, Betts R et al. Safety and efficacy of the neuraminadase inhibitor GG 167 in experimental human influenza. Journal of the American Medical Association 1996; 275: 295-299.
15. Wiselka M, Nicolson K, Kent J, Cookson J, Tyrrell D. Prophylactic intranasal alpha 2-interferon and viral exacerbations of chronic respiratory disease. Thorax 1991; 46: 706-711.
16. Fleming D, Cross K. Respiratory syncytial virus or influenza? Lancet 1993; 342: 1507-1510.
17. Capsey L, Jones K, Snell, N. Safety and tolerance of nebulised ribavirin in clinical usage. Acta Therapeutica 1992; 18: 133-147.
18. Price H, Mathew D. Evaluation of pediatric intensive care scoring systems Intensive Care Medicine 1989; 15; 79-83
19. Wade J, McGuffin R, Springmeyer S, Newman B, Singer J, Meyers J. Treatment of cytomegaloviral pneumonia with high dose acyclovir and human leucocyte interferon. Journal of Infectious Diseases 1983; 148: 557-562.
20. Schmidt G et al. A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogenic bone marrow transplants. New England Journal of Medicine 1991; 324: 1005-1011.
21. Khan A, Khabbaz R, Armstrong L et al. Hantavirus pulmonary syndrome: The first 100 US cases. Journal of Infectious Diseases 1996; 173: 1297-1303.